A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule
E Bork, S Vest, HH Hansen - European Journal of Cancer and Clinical …, 1989 - Elsevier
Brequinar, DUP 785, is a substituted 4-quinoline carboxylic acid derivative which in
preclinical studies has shown broad antitumor activity. It is a novel antimetabolite blocking
pyrimidine nucleotide synthesis. In a clinical phase I study, 83 patients were treated on a
weekly schedule and 18 patients on a biweekly schedule. The drug was given intravenously
as a short infusion. Three patients were entered on each dose level from a starting dose of 6
mg/m 2 up to 2600 mg/m 2 weekly. The dose ranges on a biweekly schedule were 500–850 …
preclinical studies has shown broad antitumor activity. It is a novel antimetabolite blocking
pyrimidine nucleotide synthesis. In a clinical phase I study, 83 patients were treated on a
weekly schedule and 18 patients on a biweekly schedule. The drug was given intravenously
as a short infusion. Three patients were entered on each dose level from a starting dose of 6
mg/m 2 up to 2600 mg/m 2 weekly. The dose ranges on a biweekly schedule were 500–850 …
